Citigroup Inc Centessa Pharmaceuticals PLC Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Citigroup Inc holds 14,094 shares of CNTA stock, worth $241,853. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,094

Previous 1,228 1047.72%

Holding current value

$241,853

Previous $11,000 1945.45%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$8.58 - $16.99 $110,390 - $218,593	12,866 Added 1047.72%	14,094 $225,000
Q2 2024 Aug 12, 2024	BUY	$8.04 - $11.87 $8,232 - $12,154	1,024 Added 501.96%	1,228 $11,000
Q1 2024 May 10, 2024	SELL	$6.73 - $12.2 $5,350 - $9,699	-795 Reduced 79.58%	204 $2,000
Q4 2023 Feb 09, 2024	BUY	$5.52 - $8.03 $1,893 - $2,754	343 Added 52.29%	999 $7,000
Q3 2023 Nov 09, 2023	SELL	$6.01 - $8.24 $1,436 - $1,969	-239 Reduced 26.7%	656 $4,000
Q2 2023 Aug 10, 2023	BUY	$3.68 - $6.9 $1,081 - $2,028	294 Added 48.92%	895 $5,000
Q1 2023 May 11, 2023	SELL	$3.03 - $4.0 $203 - $268	-67 Reduced 10.03%	601 $2,000
Q3 2022 Nov 10, 2022	SELL	$3.8 - $5.91 $2,116 - $3,291	-557 Reduced 45.47%	668 $3,000
Q2 2022 Aug 10, 2022	BUY	$3.18 - $9.85 $998 - $3,092	314 Added 34.47%	1,225 $6,000
Q1 2022 May 12, 2022	SELL	$7.45 - $11.59 $879 - $1,367	-118 Reduced 11.47%	911 $8,000
Q4 2021 Feb 10, 2022	BUY	$10.99 - $17.54 $9,011 - $14,382	820 Added 392.34%	1,029 $12,000
Q3 2021 Nov 10, 2021	BUY	$16.7 - $23.11 $3,490 - $4,829	209 New	209 $3,000

Others Institutions Holding CNTA

# of Institutions

108

Shares Held

118M

Call Options Held

5.9K

Put Options Held

53K

View Full List

About Centessa Pharmaceuticals plc

Ticker CNTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,339,296
Market Cap $1.62B
Description
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...

More about CNTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account